Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?

Detalles Bibliográficos
Autores principales: Al Sharie, Ahmed H., Abu Mousa, Balqis M., Alomari, Ahmad O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Academy for Clinical Hematology (IACH) 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515879/
https://www.ncbi.nlm.nih.gov/pubmed/37752987
http://dx.doi.org/10.46989/001c.87501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515879/
https://www.ncbi.nlm.nih.gov/pubmed/37752987
http://dx.doi.org/10.46989/001c.87501

Ejemplares similares